Basit öğe kaydını göster

Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial

dc.contributor.authorQuartier, Pierre
dc.contributor.authorDe Benedetti, Fabrizio
dc.contributor.authorFrenkel, Joost
dc.contributor.authorCalvo, Inmaculada
dc.contributor.authorGattorno, Marco
dc.contributor.authorMoutschen, Michel
dc.contributor.authorÖZEN, SEZA
dc.contributor.authorAnton, Jordi
dc.contributor.authorKone-Paut, Isabelle
dc.contributor.authorLachmann, Helen
dc.contributor.authorHoffman, Hal M.
dc.contributor.authorBen-Chetrit, Eldad
dc.contributor.authorShcherbina, Anna
dc.contributor.authorHofer, Michael
dc.contributor.authorHashkes, Philip J.
dc.contributor.authorZeft, Andrew
dc.contributor.authorLheritier, Karine
dc.contributor.authorGong, Yankun
dc.contributor.authorSpeziale, Antonio
dc.contributor.authorJunge, Guido
dc.contributor.authorKasapcopur, Ozgur
dc.date.accessioned2021-03-05T10:30:08Z
dc.date.available2021-03-05T10:30:08Z
dc.identifier.citationDe Benedetti F., Frenkel J., Calvo I., Gattorno M., Moutschen M., Quartier P., Kasapcopur O., ÖZEN S., Anton J., Kone-Paut I., et al., "Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial", ARTHRITIS & RHEUMATOLOGY, cilt.68, 2016
dc.identifier.issn2326-5191
dc.identifier.othervv_1032021
dc.identifier.otherav_a36c8bc2-6551-49e3-bfc4-50ab2bb5b146
dc.identifier.urihttp://hdl.handle.net/20.500.12627/109393
dc.language.isoeng
dc.subjectROMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.titleEfficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial
dc.typeMakale
dc.relation.journalARTHRITIS & RHEUMATOLOGY
dc.contributor.departmentIRCCS Bambino Gesu , ,
dc.identifier.volume68
dc.contributor.firstauthorID235988


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster